A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT07638566 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
NOT_YET_RECRUITING
Status
6
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

argenx